title: Chromosomal aberrations and cancer risk: results of a cohort study from Central Europe.
abstract: A high level of chromosomal aberrations in peripheral blood lymphocytes may be an early marker of cancer risk, but data on risk of specific cancers and types of chromosomal aberrations (chromosome type and chromatid type) are limited. A total of 6,430 healthy individuals from nine laboratories in Croatia, Hungary, Lithuania, Poland, and Slovakia, included in chromosomal aberration surveys performed during 1978-2002, were followed up for cancer incidence or mortality for an average of 8.5 years; 200 cancer cases were observed. Compared with that for the low-tertile level of chromosomal aberrations, the relative risks of cancer for the medium and high tertiles were 1.78 (95% confidence interval: 1.19, 2.67) and 1.81 (95% confidence interval: 1.20, 2.73), respectively. The relative risk for chromosome-type aberrations above versus below the median was 1.50 (95% confidence interval: 1.12, 2.01), while that for chromatid-type aberrations was 0.97 (95% confidence interval: 0.72, 1.31). The analyses of risk of specific cancers were limited by small numbers, but the association was stronger for stomach cancer. This study confirms the previously reported association between level of chromosomal aberrations and cancer risk and provides novel information on the type of aberrations more strongly predictive of cancer risk and on the types of cancer more strongly predicted by chromosomal aberrations.
authors.affiliation: International Agency for Research on Cancer, Lyon, France. boffetta@iarc.fr
authors.forename: Paolo
authors.initials: P
authors.lastname: Boffetta
authors.forename: Olga
authors.initials: O
authors.lastname: van der Hel
authors.forename: Hannu
authors.initials: H
authors.lastname: Norppa
authors.forename: Eleonora
authors.initials: E
authors.lastname: Fabianova
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Fucic
authors.forename: Sarolta
authors.initials: S
authors.lastname: Gundy
authors.forename: Juozas
authors.initials: J
authors.lastname: Lazutka
authors.forename: Antonina
authors.initials: A
authors.lastname: Cebulska-Wasilewska
authors.forename: Daniela
authors.initials: D
authors.lastname: Puskailerova
authors.forename: Ariana
authors.initials: A
authors.lastname: Znaor
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Kelecsenyi
authors.forename: Juozas
authors.initials: J
authors.lastname: Kurtinaitis
authors.forename: Jadwiga
authors.initials: J
authors.lastname: Rachtan
authors.forename: Alessandra
authors.initials: A
authors.lastname: Forni
authors.forename: Roel
authors.initials: R
authors.lastname: Vermeulen
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonassi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D002869:Chromosome Aberrations / Q000706:statistics & numerical data*; D025063:Chromosome Disorders / Q000453:epidemiology* / Q000235:genetics; D003582:Cytogenetics; D005061:Europe, Eastern / Q000453:epidemiology; D005260:Female; D006306:Health Surveys; D006801:Humans; D053208:Kaplan-Meier Estimate; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000401:mortality; D016273:Occupational Exposure / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
chemical_list: D014408:Biomarkers, Tumor